Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART: Sacituzumab Govitecan With or Without Atezolizumab in Rare Genitourinary Tumors
NCT06161532Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2024
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in genitourinary tumor, sponsored by National Cancer Institute. Started Aug 2024; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
genitourinary tumor
Beyond the preview
Go deeper on NCT06161532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06161532.